<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637767</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000588063</org_study_id>
    <secondary_id>2006-003424-12</secondary_id>
    <secondary_id>EU-20820</secondary_id>
    <nct_id>NCT00637767</nct_id>
  </id_info>
  <brief_title>High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant</brief_title>
  <acronym>AntiCD-66</acronym>
  <official_title>A Randomised Phase II Clinical Trial Using Targeted Radiotherapy Delivered by an Yttrium-90 Radio-Labelled Anti-CD66 Monoclonal Antibody With High Dose Melphalan Compared to Melphalan Alone, Prior to Autologous Stem Cell Transplantation for Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Federation of Pharmaceutical Industries and Associations</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill &amp; Melinda Gates Foundation Visitor Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Periscope Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Q-Biologicals NV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southampton</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the&#xD;
      growth of cancer cells, either by killing the cells or by stopping them from dividing.&#xD;
      Radiolabeled monoclonal antibodies can find cancer cells and carry cancer-killing substances&#xD;
      to them without harming normal cells. A stem cell transplant using stem cells from the&#xD;
      patient may be able to replace blood-forming cells that were destroyed by the chemotherapy&#xD;
      and radiolabeled monoclonal antibody.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well high-dose melphalan works when&#xD;
      given with or without radiolabeled monoclonal antibody in treating patients with multiple&#xD;
      myeloma undergoing an autologous stem cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the efficacy of high-dose melphalan (200mg/m²) in combination with targeted&#xD;
           radiotherapy delivered by yttrium Y 90 anti-CD66 monoclonal antibody BW250/183, in terms&#xD;
           of disease response (complete remission rate and change in serum free light chain level&#xD;
           before and after treatment with yttrium Y 90 anti-CD66 monoclonal antibody BW250/183),&#xD;
           in patients undergoing autologous hematopoietic stem cell transplantation for multiple&#xD;
           myeloma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the toxicity profile of yttrium Y 90 anti-CD66 monoclonal antibody&#xD;
           BW250/183 in the context of autologous hematopoietic stem cell transplantation.&#xD;
&#xD;
        -  To determine the effect of targeted radiotherapy on other parameters of disease&#xD;
           response, in terms of proportion of patients with partial remission, stable disease, and&#xD;
           progressive disease, remission duration (time to disease progression), and overall&#xD;
           survival.&#xD;
&#xD;
        -  To determine the effect of targeted radiotherapy on engraftment when used in combination&#xD;
           with high-dose melphalan in patients undergoing autologous hematopoietic stem cell&#xD;
           transplantation for multiple myeloma.&#xD;
&#xD;
        -  To investigate the pharmacokinetic behavior of indium In 111 anti-CD66 monoclonal&#xD;
           antibody BW250/183 (used for dosimetry).&#xD;
&#xD;
        -  To continue to develop a dosimetry model based on single-photon emission computed&#xD;
           tomography (SPECT) and whole body gamma camera imaging following administration of the&#xD;
           radiolabeled anti-CD66 monoclonal antibody (in a subset of patients at the Southampton&#xD;
           site only).&#xD;
&#xD;
        -  To assess the proportion of patients who form human anti-murine antibodies (HAMA) after&#xD;
           treatment with targeted radiotherapy in the context of an autologous hematopoietic stem&#xD;
           cell transplantation.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to disease risk group&#xD;
      (low risk [beta-2 microglobulin and C-reactive protein &lt; 6 or either beta-2 microglobulin or&#xD;
      C-reactive protein ≥ 6] vs high risk [both beta-2 microglobulin and C-reactive protein ≥ 6]).&#xD;
      Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive a dosimetry dose of indium In 111 anti-CD66 monoclonal antibody&#xD;
           BW250/183 IV on day 1 and undergo gamma camera imaging and serial blood samples on days&#xD;
           1-5. Patients then receive a therapeutic dose of yttrium Y 90 anti-CD66 monoclonal&#xD;
           antibody BW250/183 IV once between days 9 and 16 and high-dose melphalan IV on day 28.&#xD;
           Patients then undergo autologous hematopoietic stem cell transplantation (HSCT) on day&#xD;
           30.&#xD;
&#xD;
        -  Arm II: Patients receive high-dose melphalan IV on day 1. Patients then undergo&#xD;
           autologous HSCT on day 3.&#xD;
&#xD;
      Patients in arm I undergo blood sample collection periodically for pharmacokinetic and&#xD;
      pharmacodynamic studies and analysis of human anti-murine antibody (HAMA) status.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">December 1, 2007</start_date>
  <completion_date type="Actual">October 31, 2013</completion_date>
  <primary_completion_date type="Actual">October 31, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission status pre- and post-transplantation, specifically the number of patients who achieve complete remission, as measured by the European Blood and Marrow Transplantation Organization Response Criteria</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease response, as measured by changes in serum free light chains (in those patients with serum free light chains that are informative)</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease response, including the proportion of patients with partial remission, stable disease, and progressive disease and remission duration (time to disease progression)</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment quality, as measured by time to recovery of peripheral blood neutrophils to &gt; 500/mm³ and platelets &gt; 50, 000/mm³ and duration of recovery for &gt; 180 days post-transplantation</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile of yttrium Y 90 anti-CD66 monoclonal antibody BW250/183 in the context of autologous stem cell transplantation</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of indium In 111 anti-CD66 monoclonal antibody BW250/183 as measured by serial blood samples and serial planar and single-photon emission computed tomography (SPECT) gamma camera imaging of selected organs</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of a dosimetry model based on SPECT and whole body gamma camera imaging</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who form human anti-murine antibodies (HAMA) after treatment with targeted radiotherapy in the context of an autologous hematopoietic stem cell transplantation</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>radio-labelled anti-CD66 monoclonal antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 4mg radio-labelled anti-CD66 monoclonal antibody. Plus standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No IMP - standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No IMP - standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <arm_group_label>No IMP - standard treatment</arm_group_label>
    <arm_group_label>radio-labelled anti-CD66 monoclonal antibody</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>No IMP - standard treatment</arm_group_label>
    <arm_group_label>radio-labelled anti-CD66 monoclonal antibody</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183</intervention_name>
    <arm_group_label>radio-labelled anti-CD66 monoclonal antibody</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically proven multiple myeloma (MM)&#xD;
&#xD;
          -  Scheduled to undergo autologous hematopoietic stem cell transplantation (HSCT) as&#xD;
             consolidation treatment for MM&#xD;
&#xD;
               -  Must have sufficient CD34-positive stem cells (≥ 4 x 10^6 cells per kg body&#xD;
                  weight) in cryo-storage for two autologous HSCTs&#xD;
&#xD;
          -  In partial remission (PR) after prior chemotherapy but before priming therapy for stem&#xD;
             cell mobilization&#xD;
&#xD;
               -  Patients in complete remission (CR) after prior chemotherapy are not eligible&#xD;
&#xD;
          -  Bone marrow cellularity ≥ 20%&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 24 weeks&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Neutrophils ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelets ≥ 50,000/mm³&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and/or AST ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile female patients must use effective contraception for 4 weeks prior to, during,&#xD;
             and for 6 months after completion of study treatment&#xD;
&#xD;
          -  Fertile male patients must use effective contraception during and for 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Able to cooperate with study treatment and follow up&#xD;
&#xD;
          -  Human anti-mouse antibody (HAMA) negative&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No high-risk non-malignant systemic disease&#xD;
&#xD;
          -  No other condition, that in the investigator's opinion, would make the patient an&#xD;
             unsuitable candidate for the study&#xD;
&#xD;
          -  No known HIV or hepatitis B or C seropositivity&#xD;
&#xD;
          -  No history of allergy, including an allergy to rodents or rodent proteins&#xD;
&#xD;
          -  No history of eczema or asthma&#xD;
&#xD;
          -  No history of New York Heart Association (NYHA) class III or IV cardiac disease&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
               -  Alopecia or certain grade 1 toxicities allowed&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy (except for localized pain control),&#xD;
             endocrine therapy, or immunotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior and no other concurrent chemotherapy for the underlying&#xD;
             hematological condition, except for the following:&#xD;
&#xD;
               -  Cyclophosphamide as priming for stem cell harvest&#xD;
&#xD;
               -  Thalidomide&#xD;
&#xD;
          -  More than 3 weeks since prior major thoracic and/or abdominal surgery and recovered&#xD;
&#xD;
          -  No prior high-dose therapy and autologous HSCT&#xD;
&#xD;
          -  Concurrent radiotherapy allowed for the control of bone pain&#xD;
&#xD;
               -  The irradiated lesions are not used for response evaluation&#xD;
&#xD;
          -  No other concurrent anti-cancer therapy or investigational drugs during&#xD;
             transplantation conditioning&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Orchard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Southampton NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 14, 2008</study_first_submitted>
  <study_first_submitted_qc>March 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

